Form 4: Athira Pharma Executive Mark Worthington Reports Stock Transactions

Athira Pharma's General Counsel and CCO, Mark Worthington, reports multiple transactions involving the company's stock, including acquisitions through an employee stock purchase plan and vesting of restricted stock units.

Summary

• Mark Worthington, General Counsel and CCO of Athira Pharma, reported several transactions involving the company's common stock.
• On November 18, 2024, Mr. Worthington acquired 3,651 shares at $0.55 per share through the company's Employee Stock Purchase Plan (ESPP).
• On December 31, 2024, 36,667 restricted stock units (RSUs) vested, converting into common stock.
• Also on December 31, 2024, 36,667 shares were acquired through the vesting of RSUs.
• On January 2, 2025, 8,510 shares were sold at a weighted average price of $0.5619 to cover tax obligations related to the RSU vesting.
• The total number of shares beneficially owned by Mr. Worthington after these transactions is 83,735.

Sentiment

Score: 6

Explanation: The document is neutral, reporting routine insider transactions. There are no indications of positive or negative sentiment, it is simply a report of stock activity.

Positives

• The acquisition of shares through the ESPP indicates participation in the company's growth.
• The vesting of RSUs suggests continued service and commitment by Mr. Worthington to the company.

Negatives

• The sale of 8,510 shares, while for tax obligations, reduces Mr. Worthington's direct holdings.

Risks

• Fluctuations in the stock price could impact the value of Mr. Worthington's holdings.
• Future vesting of RSUs is contingent on continued service with the company.

Future Outlook

The document does not contain any specific forward-looking statements, but it does outline the vesting schedule for the remaining RSUs.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan.
• The sale of shares was to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units and does not represent a discretionary sale by the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• The use of an Employee Stock Purchase Plan (ESPP) and Restricted Stock Units (RSUs) is a common practice for compensating employees in the biotechnology industry, similar to companies like Biogen and Amgen.
• The vesting schedule of the RSUs, with one-third vesting annually, is a typical approach to incentivize long-term commitment, comparable to vesting schedules seen at other biotech firms.
• The sale of shares to cover tax obligations is a standard practice among executives receiving equity compensation, and is not unique to Athira Pharma.

Stakeholder Impact

• Shareholders are informed of insider transactions, providing transparency.
• Employees participating in the ESPP benefit from the opportunity to purchase company stock at a discount.
• The vesting of RSUs incentivizes employees to remain with the company.

Next Steps

• The remaining two tranches of RSUs will vest on June 30, 2025, and December 31, 2025, respectively, subject to continued service.

Key Dates

Keywords

Athira Pharma, stock transactions, Form 4, insider trading, restricted stock units, employee stock purchase plan, Mark Worthington, vesting, share sale